Trials / Completed
CompletedNCT00708903
Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)
A Single Dose, Crossover, Placebo- and Moxifloxacin-Controlled Study of the Effects of HKI-272 on Cardiac Repolarization in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Puma Biotechnology, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine whether HKI-272 affects the rhythms of the heart (cardiac repolarization).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | neratinib | HKI-272 |
| OTHER | Placebo | Placebo |
| DRUG | Moxifloxacin |
Timeline
- Start date
- 2008-05-01
- Primary completion
- 2008-07-01
- Completion
- 2008-07-01
- First posted
- 2008-07-02
- Last updated
- 2012-05-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00708903. Inclusion in this directory is not an endorsement.